Ruxolitinib (JAKAVI®)
Sponsors
French Innovative Leukemia Organisation, Melbourne Health, First Affiliated Hospital of Zhejiang University, Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Stephan Grupp MD PhD
Conditions
Acute Lymphoblastic Leukemia, High RiskAcute Lymphoblastic Leukemia, RelapseAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia, High RiskAcute Myeloid Leukemia, RelapsedAplastic Anemia IdiopathicEssential ThrombocythemiaGraft vs Host Disease
Phase 1
REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2
Not yet recruitingNCT06607367
Start: 2024-10-30End: 2026-10-30Target: 20Updated: 2024-09-23
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
Not yet recruitingNCT07464951
Start: 2026-04-01End: 2030-04-30Target: 30Updated: 2026-03-11
Phase 2
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
TerminatedNCT02962388
Start: 2017-01-03End: 2021-06-28Updated: 2021-06-29
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
RecruitingNCT07366801
Start: 2025-09-03End: 2028-02-03Target: 64Updated: 2026-01-26